Genomics biomarker identification

Benkali K, Marquet P, Rerolle JP, Meur YL, Gastinel LN. A new strategy for faster urinary biomarkers identification by Nano-LC-MALDI-TOF/TOF mass spectrometry. BMC Genomics. 2008 9(1) 541. 

Advances in genomics and proteomics methodologies, directed at identifying those genes expressed at elevated levels in tumors compared to normal tissues, have led and accelerated the identification process of many potentially useful tumor biomarkers for the diagnosis and therapy. 

A primary goal of cliiucal genomics, proteomics and metabolomics is the identification of early disease biomarkers and therapeutic dmg targets. 

Nassirpour, R., et al.. Identification of tubular injury microRNA biomarkers in urine comparison of next-generation sequencing and qPCR-based profiling platforms. BMC Genomics, 2014.15 p. 485-500. 

Fagerquist, C.K., Miller, W.G., Harden, L.A., Bates, A.H., Vensel, W.H., Wang, G., Mandrell, R.E. (2005) Genomic and proteomic identification of a DNA-binding protein used in the fingerprinting of Campylobacter species and strains by MALDI-TOF-MS protein biomarker analysis. Anal. Chem., 77,4897 907. 

Another strategy for exposure assessment analysis is based on the measurable binding of pesticides or metabolites to specific ceU receptors. In the areas of hazard assessment and exposure assessment, in vitro studies to assess mechanistic processes of toxicity, have been developed. These studies utilise new and innovative technologies such as genomics, transcriptomics and proteomics which allows the identification of in vitro clusters of genes and proteins that can be induced or silenced by pesticides or metabolites. The key point in these cases is to vahdate in vitro studies with in vivo exposure assessment by testing if mechanistic responses found in vitro correlates with in vivo exposure doses. This type of integrated, mechanism-driven in vitro to in vivo approach relies extensively on the use of cell assays to develop new biomarkers. 

---